Fenofibrate - Cipher Pharmaceuticals

Drug Profile

Fenofibrate - Cipher Pharmaceuticals

Alternative Names: CIP-FENOFIBRATE; Fenomax; Lipofen

Latest Information Update: 27 Jul 2012

Price : $50

At a glance

  • Originator Cipher Pharmaceuticals
  • Class Antihyperlipidaemics; Benzophenones; Butyric acids; Fibric acid derivatives; Propionates; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hypercholesterolaemia

Most Recent Events

  • 25 Jul 2012 Fenofibrate - Cipher Pharmaceuticals is available for licensing in World (excluding Canada, USA) as of 25 Jul 2012.
  • 04 Aug 2008 ProEthic Pharmaceuticals has been acquired by Kowa
  • 03 Jun 2008 Oryx Pharmaceuticals has been acquired by Sepracor
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top